CLAIMS

1. Use of modified tripeptide or one of its pharmaceutically acceptable salts in the manufacture of a medicament for treating and/or preventing a disorder selected from:

- progeroid syndromes;
- oculopharyngeal muscular dystrophy; and,
- human cancers overexpressing SRSF1 proto-oncogene selected from breast cancer, lung cancer, prostate cancer, kidney cancer, colorectal cancer and skin cancer;

wherein said modified tripeptide is selected from Z-Leu-Leu-Leu-al (MG132), Z-Leu-Leu-nVal-al (MG115), Z-Leu-Leu-Leu-$B(OH)_2$ (MG262), or Z-Leu-Leu-Phe-al (MG110).

2. The use according to claim 1, wherein said progeroid syndrome disorders are chosen from the group consisting of Hutchinson-Gilford progeria syndrome, atypical progeria syndrome, restrictive dermopathy, Nestor-Guillermo progeria syndrome, Werner syndrome, Bloom syndrome, Rothmund-Thomson syndrome, Cockayne syndrome, Xeroderma pigmentosum and trichothiodystrophy.

3. The use according to Claims 1 or 2, wherein said modified tripeptide or one of its pharmaceutically acceptable salt, is formulated as an injectable formulation.

4. A cosmetic use of a modified tripeptide or one of its pharmaceutically acceptable salt, for attenuating physiological ageing induced by progerin or farnesylated prelamin A, wherein said modified tripeptide is selected from Z-Leu-Leu-Leu-al (MG132), Z-Leu-Leu-nVal-al (MG115), Z-Leu-Leu-Leu-$B(OH)_2$ (MG262), or Z-Leu-Leu-Phe-al (MG110).

5. The cosmetic use of Claim 4, for reducing wrinkles, file lines, and/or for preventing thinning of the skin and/or an aspect of soft and withered skin.